



Resignation of Dr Graham Kelly as Non-Executive Director

- **Dr Kelly to resign as director of the Company, effective 20 September 2022**
- **Continuing evolution as Noxopharm transitions to next stage of development**
- **Company thanks founder and former CEO for long-term contribution**

Sydney, 19 September 2022: Innovative biotech company **Noxopharm Limited (ASX:NOX)** announces Dr Graham Kelly's resignation as a non-executive director, effective 5.00pm Tuesday 20 September 2022.

The change represents the natural evolution of the Company's leadership, as it transitions to the next stage of its development.

Noxopharm Chairman Fred Bart said: "As founder, Dr Kelly has been instrumental in the growth of the Company, and we would like to thank him for his significant contributions over the years in both his CEO and Board roles. Having passed on the reins to Dr Gisela Mautner, Dr Kelly's decision is a natural evolution of our development, and we wish him all the best for his future endeavours."

Dr Kelly said: "Drug development is a business of two parts. The first part is the scientific / creative / entrepreneurial phase, involving new ideas and putting together the infrastructure to bring them into the clinic. The second part is the business side, patiently working your way through the clinic and ultimately commercialising the original ideas.

"Those two parts require different skillsets. With Noxopharm now entering the second part of its life, it was my decision to put the Company in the hands of people with different skills. In doing so, I believe that a handover needs to be complete, which is why I have decided to leave the Board.

"One of my proudest achievements is the very talented scientific team I assembled, with last week's exciting pre-clinical pancreatic results with CRO-67 an example of what they are capable of achieving, and what I have little doubt will be the start of many more to come.

"My wife and I are the Company's largest shareholders, and that is a position we intend to retain."

An Appendix 3Z for Dr Kelly will be released on 20 September 2022, the effective date of change.

-ENDS-



About Noxopharm

Noxopharm Limited (ASX:NOX) is an innovative Australian biotech company discovering and developing novel treatments for cancer and inflammation.

It has three active drug development programs: its clinical drug candidate Veyonda[®], plus two innovative technology platforms – Chroma[™] (oncology) and Sofra[™] (inflammation and autoimmunity), which provide the basis for active development of a growing pipeline of new proprietary drugs.

Noxopharm also has a major shareholding in the US biotech company Nyrada Inc (ASX:NYR), which is active in the areas of drug development for cardiovascular and neurological diseases.

To learn more, please visit: noxopharm.com

Investor, Corporate & Media enquiries:

Julian Elliott

M: 0425 840 071

E: julian.elliott@noxopharm.com

Company Secretary:

David Franks

T: +61 2 8072 1400

E: David.Franks@automicgroup.com.au

Mr Fred Bart, Chair of Noxopharm, has approved the release of this document to the market on behalf of the Board of Directors.

Forward Looking Statements

This announcement may contain forward-looking statements. You can identify these statements by the fact they use words such as “aim”, “anticipate”, “assume”, “believe”, “continue”, “could”, “estimate”, “expect”, “intend”, “may”, “plan”, “predict”, “project”, “plan”, “should”, “target”, “will” or “would” or the negative of such terms or other similar expressions. Forward-looking statements are based on estimates, projections and assumptions made by Noxopharm about circumstances and events that have not yet taken place. Although Noxopharm believes the forward-looking statements to be reasonable, they are not certain. Forward-looking statements involve known and unknown risks, uncertainties and other factors that are in some cases beyond the Company’s control (including but not limited to the COVID-19 pandemic) that could cause the actual results, performance or achievements to differ materially from those expressed or implied by the forward-looking statement.